Lipocine (NASDAQ:LPCN – Get Free Report) and Mangoceuticals (NASDAQ:MGRX – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.
Insider & Institutional Ownership
9.1% of Lipocine shares are owned by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are owned by institutional investors. 6.4% of Lipocine shares are owned by insiders. Comparatively, 16.0% of Mangoceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Lipocine and Mangoceuticals”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lipocine | $1.98 million | 8.52 | -$9.63 million | ($1.69) | -1.37 |
| Mangoceuticals | $460,000.00 | 15.05 | -$20.64 million | ($2.56) | -0.16 |
Lipocine has higher revenue and earnings than Mangoceuticals. Lipocine is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Lipocine and Mangoceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lipocine | -487.00% | -59.30% | -53.37% |
| Mangoceuticals | -4,536.70% | -109.38% | -102.40% |
Risk and Volatility
Lipocine has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, Mangoceuticals has a beta of 2.54, suggesting that its stock price is 154% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Lipocine and Mangoceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lipocine | 1 | 1 | 0 | 1 | 2.33 |
| Mangoceuticals | 1 | 0 | 0 | 0 | 1.00 |
Lipocine presently has a consensus price target of $15.00, suggesting a potential upside of 549.35%. Given Lipocine’s stronger consensus rating and higher probable upside, equities analysts clearly believe Lipocine is more favorable than Mangoceuticals.
Summary
Lipocine beats Mangoceuticals on 9 of the 14 factors compared between the two stocks.
About Lipocine
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.
About Mangoceuticals
Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.
